| Literature DB >> 35216598 |
Jun Xie1, Lei Zhang2, Zhen Liu3, Chun-Lei Lu4, Guang-Hui Xu5, Man Guo5, Xiao Lian5, Jin-Qiang Liu5, Hong-Wei Zhang6, Shi-Ying Zheng7.
Abstract
BACKGROUND: Oesophagectomy, the gold standard for oesophageal cancer treatment, causes significantly high morbidity and mortality. McKeown minimally invasive oesophagectomy (MIE) is preferred for treating oesophageal malignancies; however, limited studies with large sample sizes focusing on the surgical and oncological outcomes of this procedure have been reported. We aimed to compare the clinical safety and efficacy of McKeown MIE with those of open oesophagectomy (OE). PATIENTS AND METHODS: Overall, 338 oesophageal cancer patients matched by gender, age, location, size, and T and N stages (McKeown MIE: 169 vs OE: 169) were analysed. The clinicopathologic features, operational factors, postoperative complications, and prognoses were compared between the groups.Entities:
Keywords: McKeown MIE; Oesophageal cancer; Open oesophagectomy; Prognosis
Mesh:
Year: 2022 PMID: 35216598 PMCID: PMC8881864 DOI: 10.1186/s12957-022-02527-z
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Clinical characteristics of the patients with oesophageal cancer
| Clinical characteristics | MIE group ( | OE group ( | |
|---|---|---|---|
| Sex | 0.804 | ||
| Male | 126 (74.6%) | 124 (73.4%) | |
| Female | 43 (25.4%) | 45 (26.6%) | |
| Age | 0.229 | ||
| ≤ 49 | 16 (9.5%) | 13 (7.7%) | |
| 50–59 | 46 (27.2%) | 47 (27.8%) | |
| 60–69 | 89 (52.7%) | 78 (46.2%) | |
| 70–79 | 18 (10.7%) | 29 (17.2%) | |
| ≥ 80 | 0 (0.0%) | 2 (1.2%) | |
| Preoperative smoker | 0.446 | ||
| Yes | 79 (46.7%) | 86 (50.9%) | |
| No | 90 (53.3%) | 83 (49.1%) | |
| Tumour location (%) | 0.967 | ||
| Upper | 16 (9.5%) | 17 (10.1%) | |
| Mid | 90 (53.3%) | 91 (53.8%) | |
| Lower | 63 (37.3%) | 61 (36.1%) | |
| Preoperative diet | 0.109 | ||
| Solid | 24 (14.2%) | 20 (11.8%) | |
| Semi-liquid | 84 (49.7%) | 96 (56.8%) | |
| Total liquid | 36 (21.3%) | 41 (24.3%) | |
| Water | 25 (14.8%) | 12 (7.1%) | |
| Comorbidity | 37 (21.9%) | 28 (16.6%) | 0.214 |
| Hypertension | 16 (9.5%) | 11 (6.5%) | 0.316 |
| Diabetes | 6 (3.6%) | 7 (4.1%) | 0.777 |
| Coronary artery disease | 5 (3.0%) | 4 (2.4%) | 1.000 |
| COPD | 7 (4.1%) | 4 (2.4%) | 0.358 |
| Arrhythmia | 2 (1.2%) | 2 (1.2%) | 0.174 |
| Liver cirrhosis | 1 (0.6%) | 0 (0.0%) | 1.000 |
COPD chronic obstructive pulmonary disease
Surgical and postoperative pathologic information of the patients with oesophageal cancer
| Clinical variables | MIE group ( | OE group ( | |
|---|---|---|---|
| Substitution type | <0.01 | ||
| Entire stomach | 0 | 169 (100%) | |
| Gastric tube | 169 (100%) | 0 | |
| Anastomotic type | <0.01 | ||
| Cervical anastomosis | 169 (100%) | 0 | |
| Intrathoracic anastomosis | 0 | 169 (100%) | |
| Omentoplasty | <0.01 | ||
| Yes | 169 (100%) | 0 | |
| No | 0 | 169 (100%) | |
| Histologic type | 0.100 | ||
| Squamous cell carcinoma | 162 (95.9%) | 148 (87.6%) | |
| Adenocarcinoma | 3 (1.8%) | 10 (5.9%) | |
| Adenosquamous carcinoma | 3 (1.8%) | 5 (3.0%) | |
| Neuroendocrine carcinoma | 0 (0.0%) | 2 (1.2%) | |
| Small cell carcinoma | 1 (0.6%) | 2 (1.2%) | |
| Sarcoma | 0 (0.0%) | 2 (1.2%) | |
| Tumour size (mean ± SD, cm) | 4.78 ± 2.17 | 4.80 | 0.879 |
| T stage | 0.314 | ||
| T1 | 21 (12.4%) | 20 (11.8%) | |
| T2 | 47 (27.8%) | 49 (29.0%) | |
| T3 | 100 (59.2%) | 82 (48.5%) | |
| T4 | 1 (0.6%) | 18 (10.7%) | |
| N stage | 0.974 | ||
| N0 | 105 (62.1%) | 104 (61.5%) | |
| N1 | 53 (31.4%) | 54 (32.0%) | |
| N2 | 7 (4.1%) | 8 (4.7%) | |
| N3 | 4 (2.4%) | 3 (1.8%) |
Surgical outcomes of the patients with oesophageal cancer
| Clinical variables | MIE group ( | OE group ( | |
|---|---|---|---|
| Blood loss (median, IQR, ml) | 200.0 (150.0, 300.0) | 300.0 (250.0, 450.0) | <0.01 |
| Operative time (median, IQR, min) | 335.0 (280.0, 385.0) | 240.0 (185.0,285.0) | <0.01 |
| Lymph nodes harvested | |||
| Median (IQR) | 22 (17, 30) | 9 (6, 15) | <0.01 |
| Mean ± SD | 24.5 ± 10.0 | 11.2 ± 7.9 | <0.01 |
| Number of metastasis nodes | |||
| Median (IQR) | 0 (0, 1.0) | 0 (0, 1.0) | 0.730 |
| Mean ± SD | 1.2 ± 3.2 | 0.98 ± 2.0 | 0.406 |
| Rate of metastasis nodes | 64 (37.9%) | 67 (40.9%) | 0.577 |
| R0 resections | 169 (100%) | 169 (100%) | 1.000 |
| Reoperation | 2 (50.0%) | 2 (50.0%) | 1.000 |
Complications of the patients with oesophageal cancer
| Complications | MIE group ( | OE group ( | |
|---|---|---|---|
| Minor complication | 22 (13.0%) | 38 (22.5%) | 0.023 |
| Pneumothorax | 5 (3.0%) | 8 (4.7%) | 0.396 |
| Atelectasis | 6 (3.6%) | 5 (3.0%) | 0.759 |
| Pneumonia | 5 (3.0%) | 17 (10.1%) | 0.008 |
| Arrhythmia | 4 (2.4%) | 3 (1.8%) | 1.000 |
| Wound infection | 2 (1.2%) | 5 (3.0%) | 0.448 |
| Major complication | 30 (17.8%) | 47 (27.8%) | 0.028 |
| Pneumonia | 2 (1.2%) | 6 (3.6%) | 0.283 |
| RLN injury | 4 (2.4%) | 4 (2.4%) | 0.638 |
| Chylothorax | 3 (1.8%) | 2 (1.2%) | 1.000 |
| Anastomotic leakage | 8 (4.7%) | 24 (14.2%) | 0.003 |
| Delayed gastric emptying | 4 (2.4%) | 3 (1.8%) | 1.000 |
| Tracheo-bronchial injury | 0 (0.0%) | 3 (1.8%) | 0.248 |
| Anastomotic stricture | 7 (4.1%) | 3 (1.8%) | 0.199 |
| Respiratory failure | 2 (1.2%) | 2 (1.2%) | 1.000 |
| In-hospital/30-day mortality | 2 (1.2%) | 8 (4.7%) | 0.054 |
| Postoperative hospitalisation (days) | 10 (9, 12) | 12 (10, 15) | <0.01 |
Minor complication: Clavien–Dindo grade 1–2. Major complications: Clavien–Dindo grade 3–5
RLN recurrent laryngeal nerve
Fig. 1Comparison of overall survival between patients who underwent McKeown minimally invasive oesophagectomy and those who underwent open oesophagectomy